The box is a vise on my lane. Cash-flow-today + beta ≥0.90 + no-chasing-highs eliminates most of my bench: XOM 0.18, BMY 0.26, GILD 0.33, ADP 0.84, TJX 0.62, CMCSA 0.66 — all sub-0.90, DOA solo against the floor. The names that carry beta are either rich or reporting.

HON is the fundamental winner — thesis #23, conv 4. FY25 10-K (SEC XBRL, period-end 2025-12-31): rev $37.4B, op inc $8.13B (21.7% margin, UP YoY from $7.67B), OCF $6.41B, EPS $7.36, $12.5B cash. 4.1% fwd yield on a 23% payout — cash-flow-today, covered many times. Cheap-end: 13.7x fwd / 15.9x EV/EBITDA, ~10% off the $258.86 52w high ($232.99 last), above 50d/200d. Beta 0.93 CLEARS the floor. Mid three-way breakup catalyst. Ignore EODHD's -41.9% EPS-YoY — split/spin artifact; the filing shows op income rising.

Why not today: HON reports Q2 07-23 — today. Opening into the print trips the post-earnings sizing freeze and repeats the AAPL mistake we killed 4-0 on 07-20. TABLE for the NEXT session, post-print, ~2.5% from SPY — fixes count 15→16, adds cash-flow-today, funded from SPY, doesn't drag beta. STOP: op margin <17%, OCF <$5B, breakup delayed/cancelled, or -15% rel.

Rejected on discipline: TXN 49.8x/38.6x & ADI 56.8x — near highs, won't pay. CSCO beta 1.007 clean & reports 08-12 clear, but 23.6x fwd / 25x EV-EBITDA at its 52w high on AI-networking momentum — chasing the top. QUAL beta 0.90 sits ON the floor (basket drags to 0.9089) and near its own high — thin edge.

I'm not forcing a weak name into the count today. The floor is what's killing my value bench. Bring HON clean next session and it fixes count, cash, and the active gap in one motion. Daniel — flag HON for the next agenda, post-print.

Filing CME full close + HD 2.5% open as one inseparable pair. Theses #22 (CME retire) + #21 (HD).

This is the recycle I've owed since 06-18. It kept getting blocked because closing CME solo drops us to 13 vs the 18-name min-holdings floor. Pairing it one-for-one with HD fixes that: CME out, HD in, count holds at 14, no floor trip. And CME reports 07-22 — I want out before the print, not resizing into it under the freeze. Today is the window.

GATE (live check_basket_risk): clears, zero breaches.

• Beta 0.9101 → 0.9039 — holds the 0.90 floor (HD β0.951 lifts; CME β0.26 leaving is the tighter constraint, still clears with a whisker).
• Cash 1.74% → 4.09% — rebuilds the SGOV residual well inside [2%,10%].
• Consumer Discretionary 7.4% → 9.6% — closes most of our -3.6pp-most-underweight, worst active-bleeding sector.
• Financials 19.7% → 17.0% — trims the +6.7pp overweight; V/GS/SPGI engine untouched.
• Count 14, top-5 78.6% → 76.1%.

Why CME goes (thesis #22, conv 1): β0.26 dead money — -6.43% since entry, -16.1bps total / -12.5bps active since inception, second-worst detractor behind only SPY. Fine business, no live thesis. Q2 07-22 forces it.

Why HD (thesis #21, conv 4, FY25 10-K SEC XBRL, period-end 2026-02-01): rev $164.7B, op inc $20.9B (~12.7% margin), NI $14.16B, dil EPS $14.23, OCF $16.3B, 2.75% aristocrat. Equity thin by design (buybacks) so ROE screens >100% — honest read is ~13% op margin + $16B+ OCF every year. Fwd PE 22.8x, EV/EBITDA 15.9x — quality, not cheap-end, so conv 4. Why now: ~$339 vs $418 52w high — ~19% drawdown, between 50d ($326) and 200d ($352). FY25 EPS -4.6% YoY is a rate-sensitive big-ticket cyclical soft patch, NOT a franchise crack. Buying the trough of a good business. Earnings 08-18, outside freeze. STOP: comps structurally negative, op margin <~11%, OCF <~$13B, or -15% rel.

Separately — GS, reaffirming hold-not-chase. My top since-inception name (+11.1bps active), Q2 gapped it on a 45% beat. A resize clears the gate but I won't chase the gap-up — hold GS, don't add at the high. Same discipline as 07-16.

Daniel, Priya, Iris — your names. Then to the vote.

Filing HD 2.5% open + SPY 68.8%→65.8% resize as an inseparable pair. Thesis #20.

This is the count-and-passive→active work the campaign owes: 14→15 names, index dollars into vetted active quality, in Consumer Discretionary where we're -3.4pp underweight and have bled active return.

GATE (live check_basket_risk): clears direction-aware.

• Beta 0.9215 → 0.9168 — holds the 0.90 floor (HD β0.951 lifts, doesn't fight it).
• Cash 1.72% → 2.19% — the SPY trim rebuilds the SGOV residual back inside [2%,10%].
• Consumer Discretionary 7.6% → 9.7%, closing the underweight; TMT/financials untouched.
• 14→15 names, top-5 79.9% → 77.0%.
• Only flagged breach is the pre-existing SPY single-name cap, which the trim REDUCES → clears — same logic as the 07-06 MSFT/SPY and 07-09 GOOGL/SPY pairs.

Franchise (FY25 10-K, SEC XBRL, period-end 2026-02-01): rev $164.7B, op inc $20.9B (~12.7% margin), NI $14.16B, dil EPS $14.23, OCF $16.3B, 2.76% dividend (aristocrat). Equity is thin by design (buybacks) so ROE screens >100% — the honest read is ~13% op margin and $16B+ OCF every year. Fwd PE 22.7x, EV/EBITDA 15.9x — reasonable for the quality, not the cheap end, so conv 4.

Why now: ~$341 vs a $418 52w high — a ~18% drawdown, sitting between the 50d ($324.5) and 200d ($352.8). Rate-sensitive housing/big-ticket cycle at a trough (FY25 EPS -4% YoY, rev +4.8%) — a cyclical soft patch, NOT a franchise crack. Buying the trough of a good business. Next earnings 08-18, well outside the freeze.

STOP: comps turning structurally negative, op margin <~11%, OCF <~$13B, or -15% rel.

Separately — GS: my top since-inception name (+10.2%) just printed Q2 $20.98 vs $14.47 (+45%), its fourth straight double-digit beat, IB and trading confirmed. But it gapped to $1,140→$1,152 on the print — a re-rate off the beat, not a dislocation. A resize to 3.3% clears, but I won't chase the gap-up; hold GS, don't add at the high. Discipline is the same as always.

Daniel, Priya, Iris — your names. Then to the vote.

Filing GOOGL 2.5% open + SPY 71.5%→68.1% resize as an inseparable pair. Thesis #19.

This is the count-floor advance the campaign owes — 13→14 names, and unlike the last two sessions it's not a 1-in-1-out. It also does the passive-into-active work Daniel keeps flagging: grind the SPY albatross (-18.6bps active since inception) into vetted active quality, in Comm Svcs where we're -2.6pp underweight — not a fifth financial while we sit +6.9pp over SPY.

GATE (live check_basket_risk): clears direction-aware.

• Beta 0.9125 → 0.9103 — holds the 0.90 floor (GOOGL β1.247 lifts, doesn't fight it).
• Cash 1.71% → 2.59% — cures Iris's sub-floor warn (#42) in the same trade.
• Comm Svcs 6.4% → 8.6%; TMT stays underweight, financials untouched.
• 13→14 names, top-5 78.9%.
• Only flagged breach is the pre-existing SPY single-name cap, which the trim REDUCES → clears, same logic as the 07-06 MSFT/SPY pair.

Franchise (FY25, 10-K via SEC XBRL): rev $350.0B (+14%), op inc $129.0B (~37% margin), NI $132.2B, dil EPS $10.81, OCF $164.7B, ROE ~32%, $30.7B cash. Self-funding compounder. Fwd PE ~25.5x, EV/EBITDA ~19.8x — reasonable megacap quality, not the cheap end, so conv 4 not 5.

Why now: ran to a $408 52w high, sold to $330 on 06-26 (114M sh washout), reclaimed to ~$362 — above the 200d ($318), holding a higher low. Tape dislocation, franchise intact.

Data flag on the record: the 04-29 "+102% EPS surprise" ($5.11 vs $2.53 est) is a one-time item, NOT run-rate — clean quarterly EPS ~$2.30–2.87. Don't underwrite it on that print.

STOP: Q2 prints 07-22 (est $2.86), 13d out — outside the freeze today, freezes ~07-21, no add after next Mon. Kill on Search/YouTube ad rev down y/y, Cloud growth <~20% with margin give-back, an adverse antitrust structural remedy, or -15% rel.

Daniel, Priya, Iris — your names. Then to the vote.

Filing the basket I put up 06-29 that never reached the floor — because GS held the dislocation and CME kept bleeding. Both facts make the trade better, not worse.

Checked live (check_basket_risk): would_clear TRUE, zero breaches.

• Book beta 0.9058 → 0.9006 — holds the 0.90 floor.
• Cash 1.63% → 3.76% — cures the sub-floor breach Iris/ops flagged at the open, in the same trade.
• Top-5 87.5% → 84.1%. Count holds at 11 (1-in-1-out).

Leg 1 — CME close (β0.26, -16.1%, -37.7bps active since inception). My standing cut since 06-18 and ops' stop-watch item — ~200bps off the -2000 review line and closing. I checked the wire: CEO succession (Fitzpatrick named), some analyst growth notes, but it led financial-sector losers in Q2. No franchise thesis left to defend on a β0.26 dead-money financial. Crystallizes ~-$4.0k realized — a loss already on the mark. The honest funding source.

Leg 2 — GS 2.5% open, conv 4. GS closed $1,019.61 on 07-01 — the SAME level as its 06-26 dislocation, ~9% off the $1,125 52w high, on the 50d ($995), well above the 200d ($887). It held the pullback a full WEEK without a franchise crack — this is exactly the tape-divorced-from-franchise setup I held out for, and unlike ABBV/GS-at-the-high it did NOT run back up. FY25 (SEC XBRL): NI $17.18B, dil EPS $51.32, equity $125B, ROE 14.6%; TTM EPS $54.72, EPS +24% YoY, rev +14.5%. Fwd 17.2x, P/B 2.74. β1.291 — cheap-ish quality cyclical, not junk-beta.

Leg 3 — GILD 1.01%→2.0% resize. The pre-committed second β0.33 low-vol leg that only seats paired with a β≥1.15 name. GS is that name — GS's β1.29 dollars carry GILD's β0.33 leg over the floor. 39% op margin, ~$10B OCF, ROE 43%, fwd ~15x.

FRAME (Priya 07-02): reals 2.20 firmly >2.00, low-vol ON, 10yr 4.44, OAS 2.74. GS = quality cyclical on a dislocation; GILD = low-vol ballast; CME out = upgrading a β0.26/-16% drag to a β1.29 quality name. All three fit.

STOP on GS: Q2 prints 07-14 (est $13.78), 12 days out — outside the T+1 freeze, buying 9% off the high WITH runway, not the FDX night-before binary. Kill on a Q2 miss on a franchise line (IB/trading rev down y/y), ROE structurally <11%, or -15% rel.

Daniel — same structure you filed 06-29, still clears. To the vote.

Two legs as a basket — and it clears. would_clear true, zero breaches, beta 0.9066→0.9068, 11→12 names, top-5 84%.

Leg 1 — GS 2.5% of NAV, open, conv 4. The β1.291 quality unlock the campaign has waited on since 06-18.

WHY NOW: GS closed $1,019.61 on 06-26 — down 4.3% on the day, ~8% off the $1,125 52w high, on a market-wide risk-off move. The wire shows NO GS-specific crack — it sold with the financials tape, not on a franchise problem. This is the SAME name I refused to chase on 06-22 when it sat $1,096 AT its high; I said I wanted a real dislocation, not the top — and I got one. Tape divorced from franchise.

FRANCHISE (FY25, 10-K via SEC XBRL): NI $17.18B (from $14.28B), dil EPS $51.32, equity $125B, ROE ~14%. Trailing PE 18.6x, fwd 17.3x, P/B 2.76x — reasonable, NOT the ABBV chase (ABBV ran to its 52w high $253.35 on 52.6M sh 06-26, +13.6% window — OFF the table, same discipline as always). Note: GS OCF screens negative — broker-dealer balance-sheet artifact, net income is the right earnings read.

BACKDROP: US share sales hit a record ~$251B at midyear — strong issuance/IPO tape feeds IB + equities, the lines behind four straight double-digit beats (+8% to +19%).

Leg 2 — GILD 1.02%→2.0% resize. The pre-committed second 1.0% low-vol leg (β0.33) that only seats paired with a β≥1.15 name. GS is that name. 39% op margin, ~$10B OCF, ROE 43%, fwd ~15x. Conv 4, unchanged.

GATE (live):

• GS 2.5% solo: clears, zero breaches.
• GS 2.5% + GILD→2.0% basket: clears, beta 0.9068, top-5 84%, 12 names.

One high-beta name unlocks two adds — the wall I've held since 06-18, honestly cleared. Cash stays 1.66% (both funded from... see note below).

FUNDING NOTE for the chair: the basket as tested holds cash at 1.66% — under the 2% floor. If the room wants the 2-3% SGOV residual rebuilt this session, fund GS partly from an SPY-core trim rather than cash; I'll defer the exact funding mix to Daniel's sizing call. The structure (GS carries GILD over the floor) holds either way.

STOP: GS Q2 prints 07-14 (est $13.64) — 15 days out, outside the freeze. I'm buying 8% off the high WITH two weeks of runway, not the night-before binary I refused on FDX. Kill if Q2 misses on a franchise line (IB/trading rev down y/y, not a provision), ROE structurally <~11%, or -15% rel.

FRAME (Priya 06-29): reals eased to 2.19 off the cycle high but still restrictive, low-vol ON, 2y-led steepener. GS = cheap-ish high-quality cyclical financial on a dislocation, not junk-beta. To the vote.

FDX 2.5% of NAV, funded from cash, conv 4 — the unlock the campaign has waited on since 06-18.

Why now: FDX printed fiscal Q4 06-23 at $6.31 vs $5.95 est (+6%, 5th straight beat) and the tape SOLD it — 328.78 (06-22) → 317.24 (06-23) → 316.83 (06-24) on ~6.0M sh (vs ~2M typical). Wire pins it on softer margins + Freight-spinoff worry; BofA: 'strong underlying momentum,' move is 'near-term noise.' This is cash-flow-divorced-from-franchise on a known number — NOT the gap-up-on-a-beat I said I'd pass (the GS pattern). At $316.83 it sits on the 50d ($316.79), well over the 200d ($259.83): support, not a high.

Franchise (FY25, 10-K via SEC XBRL): rev $87.9B, op inc $5.2B, NI $4.1B, dil EPS $16.81, OCF $7.0B. Cheap: EV/EBITDA 9.9, fwd PE 14.4, P/S 0.82. β1.299.

Gate: FDX 2.5% solo clears, no breaches — lifts book beta 0.899 → 0.9066, back inside [0.90,1.15]; 10→11 names.

Correction to the chair, on the record: the FDX + GILD-2nd-leg pair does NOT clear. Tested: FDX 2.0% + GILD→2.0% returns beta 0.8986, veto — GILD's 0.33β dollars from cash drag harder than FDX lifts. The honest structure is FDX 2.5% solo for the unlock; GILD's second 1.0% stays pre-committed for a second high-beta name. One name, one add today — I won't dress up a failing basket.

Stop: kill FY26 OCF <~$6B or spinoff strands cost at RemainCo; -15% rel; secular margin compression retires it. Next print ~Sept (fiscal Q1 FY27).

BMY conv-4 defended carry, rides as-is (β0.26 can't be topped). ABBV/GS re-rated — watch only.

Daniel asked me on the record to source a quality cyclical / higher-beta financial (β≥1.15, conv≥3) to unlock GILD's second 1.0%. I worked four candidates to the filings and the live tape — and the discipline answer is: no buy I'll put my name on today.

GS — math works, tape doesn't. Beta 1.291, genuine franchise (FY25 SEC XBRL: NI $17.2B, dil EPS $51.32, ROE ~14.5%). The basket GILD→2.0% + GS 2.0% clears the gate (beta 0.9005, just over the floor). But GS closed $1,096.56 on 06-18, +22.4% over the window, sitting at its 52-week high. That is not a dislocation, it's a chase — same reason I won't touch ABBV up here. "Tape divorced from franchise" does not describe a name up 22% in two months. Pass.

FDX — the right kind of name, wrong day. Beta 1.299, and unlike GS it's cheap: fwd PE ~14.8, EV/EBITDA ~10, FY25 OCF $7.0B (SEC XBRL), four straight beats (+5 to +26%). This is the high-beta quality cyclical the campaign needs. But it prints fiscal Q4 tomorrow, 2026-06-23 (est EPS $5.95). I do not open a new position the night before a binary print. Filed a conv-3 thesis; revisit post-print — a soft-quarter gap toward the high-$280s/$290s (where it traded on 05-04) is the entry, and it would unlock GILD's leg cleanly.

SCHW (β0.77) and APD (β0.75) don't clear the floor requirement; EMR (β1.25) is quality but 34x trailing / 19x EV/EBITDA — no dislocation. None advance the unlock.

BMY — my actual conviction-add today, blocked only by the floor. Closed $54.00 on 06-18, a fresh low, on a 31.7M-share capitulation day. FY25 OCF $14.16B, fwd ~9x, 4.5% yield. Drawdown is tape, not thesis — nothing broke. But at β0.26, topping it pushes the book under 0.90, so it rides only paired with the high-beta unlock I don't have. Carry 2.34%, defended, conviction 4. Print 07-30.

Net: GILD's second 1.0% stays pre-committed and unfiled — not for lack of a thesis, for lack of a buyable high-beta name this morning. I won't fake the offset off the ETN lever into reals 2.23. Watch list: FDX (post-06-23 print), GS (want a real pullback, not the high), ABBV ($205-210, print 07-30).

My theme is on the floor and working — BMY 2.48% (+1.3%, $57.13, +8.0bps active inception), GIS 2.0% (+2.0%, $34.51, +7.7bps active, +3.0bps since last meeting). I don't slot-fill; here's the honest read on three Health Care candidates worked to the filings + live tape.

LEAD — GILD (Health Care, new). The pullback I wanted finally printed. $124.77 (06-12), -3.8% over the window, through the 200d (~$129.2), $121.39 low 06-10. Franchise is genuine, FY25 10-K (SEC XBRL): rev $29.4B, op income $10.0B = 39% op margin, NI $8.5B / $6.78 dil (clean swing from FY24's $0.38 IPR&D-writeoff noise), OCF $10.0B, ROE 43%, fwd PE 15.2, beta 0.331, 2.6% covered yield. Conviction 3 — good-business-at-fair-price, not a GIS/BMY deep dislocation, so I size it honestly.

The catch — beta floor, not a thesis flaw. GILD solo at 2.0-2.5% tips book beta under 0.90 (2.5%→0.891; 2.0%→0.895). SPY-funded makes it worse (trim beta-1.0 toward beta-0.33). GILD 2.0% + 50bp ETN bump still lands 0.896. Daniel — this is your lane: GILD only clears paired with a higher-beta offset — trim SPGI (1.105) or V (0.784), or a cyclical bump you're comfortable with. I will NOT manufacture room by leaning ETN into rising reals/sticky vol — you've killed that correctly twice. If you can structure a beta-neutral pair that lands ≥0.90, I co-sponsor GILD 2.0% today. If not, it's a clean WATCH at this level.

GIS add — still blocked. Resize 2.0%→2.5% trips the Staples sector cap (confirmed on the gate, 1.6x SPY). Only opens on a PEP trim, and PEP at 2.44% / -0.15% has no fresh dislocation to fund a rotation. Carry GIS 2.0%.

ABBV — still re-rated, still won't chase. $227.73, +6.5% over the window, near 52w high, above both MAs. "Tape divorced from franchise" doesn't describe a name up 6.5%. Want $205-210 on no news. Print 07-30.

Call: I table GILD as the lead but file no trade I can't clear solo — handing Daniel the beta-paired structure. Carry GIS 2.0%, BMY 2.48%. Discipline over slot-filling.

My theme, unchanged and now actionable: cash-flow yield the tape has divorced from the franchise, outside the full Financials sleeve. Two names, both filing-grounded, both clearing the gate today.

LEAD — BMY 2.5% (Health Care, new). Bristol-Myers is the cleanest expression of the theme on my sheet. The tape prices a patent cliff as if the cash stops — forward PE 9.1 vs trailing 15.8 — into a business that printed $14.2B operating cash flow (FY2025 10-K, SEC XBRL). Revenue flat at $48.2B, net income swung to $7.05B / $3.46 EPS from a -$8.9B GAAP loss that was acquired-IPR&D writeoff noise, not operations. 33% op margin, 38.7% ROE, 4.5% fwd yield, beta 0.238. Price $55.60, mid-range vs $41–$62, below both MAs. Recent prints BEAT (Q1 +13.9%). Low-vol defensive, fits Priya's late-cycle/sticky-vol frame, and it fills the open Health Care band (was -1.7pp, zero active names → ~11.3%, right at SPY). Clears clean at 2.5% (would_clear, no breaches). Kill: FY2026 OCF <~$11B. Stop -15% rel. Next print 07-30.

PAIR — GIS 2.0% + PEP trim 2.62%→1.3% (Staples). GIS has been band-blocked for weeks; trimming PEP opens the Staples room. $33.82, >35% off high, 8.1x, 7%+ fwd yield, 23.6% ROE, beta ~0 — the deepest dislocation I carry, PEP-style one notch more distressed, OCF $2.92B held (FY2025 XBRL). The GIS-2.0%/PEP-1.3% pair clears the gate. Conviction is 4 and I'd want 2.5% — the only thing capping GIS at 2.0% is the beta floor: the full slate (BMY+GIS+PEP-trim) tips book beta to 0.899, one bp under 0.90. At GIS 2.0% it sits 0.904, inside. Daniel — that's your lane: if you want GIS at full 2.5%, the ETN beta lever offsets the drag. I'm handing you a slate that clears as-is; you size/pair the beta.

Not slot-filling — both names underwritten to the cash, not the price. Theses filed (BMY conv 4 #10, GIS conv 4 #11).

My theme is unchanged — cash-flow yield the tape divorced from the franchise, outside the full Financials sleeve. But I worked three candidates to the filings and the live tape this session and none clears as a conviction lead today. I won't manufacture a slot-filler. Here's the honest read so the room isn't waiting on me:

ABBV — re-rated, won't chase. This was my flagged lead. The dislocation closed before I could lead it: ABBV printed $227.23 (06-05), +6.7% in three sessions off the early-June base, now ~9% above its $208.81 50-day and back in the upper half of the $176–$239 range. The franchise is genuine — FY2025 SEC XBRL: rev $61.2B, OCF $19.0B, 32% op margin, fwd PE 15.8, div $6.92/3.1%, beta 0.31 (GAAP optics are noise: $2.36 EPS, neg book equity from IPR&D/amort). But "tape divorced from franchise" doesn't describe a name that just rallied 7%. Health Care has band room (9.3% vs 11% SPY), so this is purely price discipline. Watch; I'd want $205–$210 on no news. Next print 07-30.

GIS — high-conviction watch, BAND-BLOCKED. This is the real dislocation: $33.15, -26% over four months, off a $31.75 low vs $52.23 high — a >35% drawdown. FY2025 (May) 10-K XBRL: rev $19.5B, OCF $2.92B, 17% op margin, 8.1x trailing, 7.3% forward yield, 23.6% ROE, beta ~0 (-0.04). Textbook PEP-style dislocation, one notch more distressed. The gate vetoes it — a second Staples name on PEP pushes the sector past 1.6x SPY; GIS only clears at ~1.0%, below conviction and crowding out future PEP. Conviction 4, but it needs Staples band-room (a Staples roll-off or PEP resize) before I can lead it at size. Catalyst: fiscal Q4 print 07-01, est $0.81.

CVX — scratched. Energy band (XOM already there) blocks a second name, and it isn't even cheap — $187 near range highs, 32x trailing on a trough year. Not a dislocation.

Bottom line: cash is at the 0.10% floor breach, so the SPY-trim mechanism funds whatever the room buys regardless. I'm deferring to Daniel/Priya's legs this session and keeping my next dollar for GIS the moment the Staples band opens. Theses filed on GIS (conv 4) and ABBV (conv 3) with full primary-source numbers.

One name tabled for today's vote — my highest-conviction non-financials idea. Every new dollar has to come from outside the full Financials sleeve (6.5pp active), and this is step one.

PEP — buy 2.5%, conv 4. Snack-franchise + beverage system; Frito-Lay/Quaker is the crown jewel — pricing power a private label can't dislodge. FY2025 10-K (SEC XBRL): revenue $93.9B, gross $50.9B (~54%), op inc $11.5B (~12%, down from $12.9B), NI $8.24B, diluted EPS $6.00 (off $6.95 — an earnings air-pocket). The key line: OCF $12.1B held flat vs $12.5B prior while EPS sagged. Why now: stock -15% over 3 months (168 adj → 142.54 on 6/3), printing fresh lows — market extrapolating the EPS dip into a cash engine that didn't move. Fits Priya's late-cycle/real-rate frame: low-beta, durable cash-flow yield. Staples is underweight (5.4% vs SPY 6.0%) — active share outside Financials. Stop: -15% rel; wrong if FY2026 OCF breaks <$11B. Gate clears at 2.5% (would_clear, no breaches).

Held back: ABBV — clean SEC numbers ($61.2B rev, $19.0B OCF) but messy GAAP (neg book equity, $2.36 EPS) and EODHD threw 502s all turn, so I couldn't verify the live price/yield/earnings date. Won't lead a vote without anchoring the tape. ABBV + COST (50x) stay watches.

Data note: EODHD fundamentals/corp-events/some price all 502 today — PEP case is SEC-XBRL primary plus a working PEP price series.

Three starter theses filed for today's vote, all from FY2025 10-Ks (SEC XBRL), all consistent with Priya's late-cycle / real-rate frame.

V — buy 3.0%, conv 5. VisaNet rails, clip of volume, no credit risk. $40.0B rev / $24.0B op inc (~60% op margin) / $23.1B OCF vs $20.1B NI — >100% cash conversion. Owners' earnings I can count when reals >2%; +17% rev YoY; beta 0.78. 28x trailing — pay up for quality, not cheap-and-bad. Clears gate at 3%.

XOM — buy 2.0%, conv 4. Inflation-hedge leg. $52.0B OCF held >$50B despite softer crude; ~4% float retired YoY; 2.8% yield; beta 0.18. Underwrite the distribution, not the oil tape. NB: 3% trips the energy sector-vs-SPY band (energy ~4% of index) — sized to 2% to clear and to avoid chasing with oil -4% on the month.

CME — buy 2.5%, conv 4. Counter-cyclical toll booth that monetizes the bear-steepener. $6.52B rev / ~65% op margin / $11.16 EPS. Rate-repricing => rate-complex hedging volume. Beta 0.26. Ignore the $198B asset gross-up (clearing collateral). Tell to watch: quarterly rate-complex ADV.

Structure flag for Daniel/Iris: V + CME both Financial Services (~5.5% combined) — each clears standalone vs the gate; watch the financials band as the book fills. COST stays a watch (50x; step in on a 20% drawdown).

07-23 VOTE — #96 HD resize 2.47%→3.2%, APPROVE (my name, executed clean)

The recycle I've owed since 06-18, finally fileable. Daniel's structure: HD 2.47%→3.2% (~+73bps, ~$728k notional), funded from SPY trim 65.18→64.4%. Ops confirms live math: β0.9106→0.9088 (12bps above floor), cash 1.78→2.22% (in band), SPY narrows not widens. Single-name gate zero breaches; SPY band residual is pre-existing and IMPROVES. HD thesis #21 intact: live $331.45, ~21% off $418 high, wedged 50d($327)/200d($351), FY25 rev $164.7B, ~12.7% op margin, $16.3B OCF, 2.81% aristocrat yield/~63% payout. -4.6% EPS-YoY = rate-sensitive big-ticket cyclical soft patch, NOT a franchise crack. Reports 08-18, clear of freeze. Room 4-0-shaped (Priya, Iris, Daniel, ops all constructive). Buying the trough. VOTE approve.

07-23 VOTE — #96 HD resize 2.47%→3.2%, aye (at deeper trim)

My name, finally executable as a clean add. Daniel re-filed HD as a resize funded from SPY. As he filed it (SPY→64.5%) cash lands 1.73%, under the 2% floor — DOESN'T clear (basket check confirmed cash-band breach). Fix: trim SPY to 63.75% instead — cash rebuilds to 2.48% (in band), beta 0.9036 (above floor), HD to 3.2%. Only residual flag is the SPY single-name cap, the standing 65% index-sleeve artifact that pre-exists and IMPROVES 65.2%→63.75%, so no veto. HD thesis intact: $331.45 live, ~21% off $418 high, between 50d/200d, rev +4.8%, op margin 11.9%, OCF $16.3B, 2.81% yield/63.6% payout. -4.3% EPS-YoY = rate-sensitive cyclical soft patch, not a crack. Reports 08-18 clear. Buying the trough. VOTE aye at 63.75% funding. VOTE: aye

07-23 VOTE #4 — #92 SPY trim to 65.5%, reject

Room converged 4-0-shaped again. SPY 65.2% / -17.3bps active is the albatross, but a standalone trim is a cash-creation event, not a trade — proceeds sit in SGOV at zero because nothing clears the box today (XOM 0.18, BMY 0.26, GILD 0.33 all DOA vs the 0.9106 floor). Trimming without a landing spot defers the drag, doesn't cut it. Sequencing, not thesis: next session post-HON-print, SPY→HON is the clean recycle — count 15→16, cash-flow-today, funded from index, β0.93 doesn't drag. HON stays my priority bring. VOTE reject.

VOTE: reject

07-23 VOTE #3 — #92 SPY resize to 65.5%, tabled as target not trade

Daniel tabled SPY as the recycle TARGET, correctly not a fileable trade today. My read: SPY 65.2% / -17.3bps active is the albatross, but trimming it earns nothing without a destination that clears the box, and today there is none. Bench is all sub-0.90 (XOM 0.18, BMY 0.26, GILD 0.33) — DOA vs the 0.9106 floor. HON prints today (freeze); CSCO needs HON seated first for beta. Raising idle cash below the 1.78% sub-floor without a landing spot just parks NAV — defers the drag, doesn't cut it. The fix is replacement, not cash. Hold SPY this session; next session post-HON-print, SPY→HON is the clean recycle: count 15→16, cash-flow-today, funded from index, no beta drag. No object — sequencing. HON stays my priority bring for next agenda.

07-23 VOTE #2 — #88 AAPL 2.3% open, reject (again)

Same trade I killed 07-20, re-tabled after the CME solo close vetoed at the count floor. AAPL $325.89 last, +8.9%/month, ~$9 off the $334.99 52w high, 35x fwd, prints 07-30 — eight days out. Gate clears (17 names, cash ~4.09%, β0.9055, zero breaches) but the gate was never the question; price/timing is. Room converged 4-0-shaped again — Iris, Daniel, Priya, ops all landed on price+into-print. I vote reject on the merits, not burning an objection. TMT fix stays HON post-print next session (β0.93, 13.7x, 4.1% yld, cash-flow-today, off the high, breakup catalyst). The floor is still the binding constraint on my value bench — bring HON clean next session, fixes count/cash/active gap in one motion.

07-23 VOTE — #88 AAPL 2.3% open, reject

Same trade I killed 07-20, worse timing. AAPL $325.89 last (07-22), +8.9%/month, ~$9 off the $334.99 52w high, prints 07-30 — eight days out, inside the freeze window logic. Gate clears at 2.3% (check_proposal_risk would_clear, zero breaches) but that's not the bar; discipline is. I won't chase the top into a print with our scarce active budget. Business fine — 4 straight beats, +3.6% Mar-q, Q4 est $1.88 — but fine+expensive+into-catalyst isn't a buy. TMT fix stays HON post-print next session (β0.93, 13.7x, cash-flow-today, off the high). Not burning an objection — the room's converging on table; I vote reject on the merits of price/timing. VOTE: reject

07-23 VOTE — #85 CME solo close, reject

Room converged exactly where I've been: CME (β0.26, -13.3bps since inception, 2nd-worst detractor, no live thesis) is a name we want gone, but the SOLO close drops count 15→14 vs the 18 floor while we're already 2 under. Fixes nothing, buys nothing this week — CME idle loses us zero. Cash-from-CME wouldn't rebuild the 2% floor either. Plumbing veto, not thesis; I agree with the block, not burning an objection. CME printed 07-22 so the earnings clock is off. Next session: bring CME→[beta-≥0.90 cash-flow-today add] as an inseparable pair — fixes count, cash, and an active gap in one motion. VOTE reject.

VOTE: reject

07-23 CME — solo close still blocked at the count floor; hold one more session, pair it next

The room converged where I've been since 06-18: CME (β0.26, -13.3bps since inception, 2nd-worst detractor, no live thesis) is a name we want gone, but closing it SOLO drops count 15→14 vs the 18 min-holdings floor. Plumbing veto, not thesis. I did NOT burn an objection — I agree with the block. Key change: CME reported 07-22, so the print I wanted to beat is behind us — no more time pressure. The right structure is my 07-20 pair: CME out funds a cash-flow-today name that clears the 0.90 floor. HON was it, but HON printed TODAY (freeze). So: hold CME one more session, bring CME→HON as an inseparable pair next session post-print. Fixes count, cash (1.78% sub-floor), and an active gap in one motion. Book β0.9106 pinned on floor — that's why solo low-beta closes and adds are both DOA.

07-23 PROPOSE — the beta floor ate my value bench; HON tabled for NEXT session, not today

The box is genuinely binding and it works against my style. Cash-flow-today + no-chasing-highs + beta≥0.90 is a three-way vise: my best owner-earnings names — XOM 0.18, BMY 0.26, GILD 0.33, ADP 0.84, TJX 0.62, CMCSA 0.66 — are ALL sub-0.90, DOA solo against the 0.90 floor (book 0.9106). The names that carry beta are either rich or reporting.

Screened MSFT-caliber compounders below own history:

• HON — the fundamental winner. FY25 10-K (SEC XBRL): rev $37.4B, op inc $8.13B (21.7% margin, UP YoY), OCF $6.41B, EPS $7.36, $12.5B cash. 13.7x fwd / 15.9x EV/EBITDA — cheap-end franchise, 4.1% yield / 23% payout. Beta 0.93 CLEARS the floor. Mid-breakup catalyst. BUT it reports TODAY (07-23) — buying into the print trips the freeze and is the exact AAPL mistake I killed on 07-20. Filed thesis #23 conv 4, TABLED for next session post-print, ~2.5% from SPY.
• TXN 49.8x/38.6x, near high — pass. ADI 56.8x, near high — pass. CSCO beta 1.007 clean but 23.6x/25x EV-EBITDA at the 52w high on AI-networking momentum — I won't chase it. QUAL beta 0.90 sits ON the floor and basket-checked to 0.9089 (drags it), plus near its own high — a rebadged SPY tilt, thin edge.

Verdict: I do NOT force a weak name into the count today. Better to tell the room the floor is the binding constraint on my lane and bring HON clean next session. On book: GIS +19.3 / BMY +20.8 / V +33.8 active carrying us; GOOGL -7.3 + Comm Svcs flagged, watching not adding; HD trough intact; GS won't chase $1,098.

07-23 FRAME — cash-flow-today is the whole tilt

Regime unchanged and it's the brief: reals 2.37, fourth-week cycle high. Duration cap on → I buy owner-earnings that land this year, not discounted growth. GIS (+19.3bps active, β-0.034) and BMY (+20.8) are the tilt working. The box binds hard this time: count 15/18 (2 under), cash 1.78% sub-floor, beta 0.911 ON the 0.90 floor — Daniel's ask is 2+ quality names, β≥0.90 each, funded from SPY. That last clause is the trap: my best cash-flow names are LOW beta (XOM 0.18, BMY 0.26, GILD 0.33) — they're DOA solo against the floor. So phase 4 I need quality that's ALSO ~market-beta. Screening MSFT-caliber compounders below own history. On book: GOOGL conv holds but -7.3bps active + Comm Svcs flagged — watching not adding. HD trough thesis intact. GS won't chase $1,098 +6%. SPY 65.2% / -17.3bps active is still the enemy — every name I bring steps off it.